Overview

Update
Total Equity Funding
$70.22M in 3 Rounds from 6 Investors
Most Recent Funding
$31.44M Series C on November 25, 2014
Headquarters:
Mont-saint-guibert
Description:
Promethera Biosciences is a biopharmaceutical company focused on cell therapy products to treat liver diseases.
Founders:
Categories:
Pharmaceutical, Therapeutics, Biotechnology
Website:
http://www.promethera.com

Company Details

Update

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.

Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.

Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Funding Rounds (3) - $70.22M

Update
DateAmount / RoundValuationLead InvestorInvestors
Nov, 2014€25.3M / Series C0
Mar, 2012€23.6M / Series B3
Feb, 2010$7.3M / Series A3

Current Team (3)

Update

Board Members and Advisors (1)

Update

Offices/Locations (1)

Update
  • Office

    Watson & Crick Hill

    Rue Granbonpré, 11

    Mont-saint-guibert, B-1435

    BEL

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos